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Abstract
Background: Malaria is a mosquito-borne infectious disease 
caused by protozoan parasites of the genus Plasmodium. As 
migration of populations from endemic areas to Europe and 
overseas recreational travel to endemic regions increase, 
there is also a growing risk of transfusion-transmitted tropi-
cal diseases by blood components. Material and Methods: 
In the present study two routine Plasmodium spp. ELISA 
(CAPTIA™ Malaria EIA, Trinity Biotech, and Malaria EIA, Bio-
Rad) were compared with a new commercial ELISA (ELISA 
IgG, EUROIMMUN). From December 1, 2015 until November 
30, 2016, 1,096 plasma samples from blood donors with a 
potential risk of malaria infection were collected at two 
blood transfusion centres in Germany and Switzerland. Re-
sults: The samples were tested comparatively with the ELISA 
from EUROIMMUN and the routine test used at the respec-
tive centre. Thirty-four of 595 (5.7%) tested blood samples 
from centre 1 and 49 of 501 (9.8%) tested blood samples 
from centre 2 showed reactivity on either or both ELISAs. All 
83 reactive samples were sent for confirmation to the Diag-
nostic Centre of the Swiss Tropical and Public Health Insti-
tute (Swiss TPH) in Basel, Switzerland. Sixteen samples, 
which previously were reactive in the routine Plasmodium 
spp. EIA assays, were proven positive after confirmation test-
ing (i.e., 4 positive and 12 inconclusive results), indicating an 
anti-Plasmodium antibody prevalence in blood donations of 
1.5%. From these 16 reactive samples, 13 were also detected 
by the index test, resulting in an assay sensitivity of 81.2%. A 
specificity of 98.6% was calculated (1,065/1,080 confirmed 
negative samples). The overall agreement with the reference 
centre was 95.8% in centre 1 and 94% in centre 2. Conclu-
sion: The comparison of the new EUROIMMUN ELISA and the 
established CAPTIA™ Malaria EIA (Trinity Biotech) and Ma-
laria EIA (BioRad) used for routine blood donor screening in 
two laboratory blood donation centres revealed that all test-
ed ELISAs show comparable sensitivities and are equally 
suitable for anti-Plasmodium antibody screening in blood 
banks. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Four different Plasmodium species are relevant for hu-
man infections: P. falciparum, P. vivax, P. ovale and P. 
malariae. Recently, P. knowlesi has emerged as an addi-
tional human pathogenic species. Though it is primarily 
zoonotic, infecting macaque monkeys, recently different 
This article is licensed under the Creative Commons Attribution 4.0 
International License (CC BY) (http://www.karger.com/Services/
OpenAccessLicense). Usage, derivative works and distribution are 
permitted provided that proper credit is given to the author and the 
original publisher.
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human populations in South-East Asia, as well as travel-
lers returning from endemic regions, were found to be 
infected. P. knowlesi was previously not recognized as a 
human pathogen and was thus probably misdiagnosed as 
the more benign and morphologically similar species P. 
malariae [1].
According to a World Health Organisation (WHO) 
report, 228 million new malaria infections occurred in 
2018; of which approximately 405,000 were fatal. Trans-
fusion of contaminated blood components is known to be 
a possible mode of human-to-human transmission. The 
incidence of transfusion-transmitted malaria (TTM) is 
particularly high in endemic regions, but there is also an 
increasing risk in non-endemic countries. This is primar-
ily due to the increased number of migrants from endem-
ic areas, as well as a rise in the number of travellers visiting 
endemic countries. Indeed, numerous cases of TTM from 
around the globe have been reported during the last de-
cade (e.g., Brazil, Italy, Canada, Switzerland, the UK, Ma-
laysia, and France) [2–8]. Although rare, TTM poses a 
risk to blood transfusion services worldwide, particularly 
since TTM cases are the consequence of infections from 
“semi-immune” donors who do not show clinical symp-
toms and who often have undetectable levels of malaria 
parasites circulating in their blood [4, 5, 8–11].
According to the current European regulations, it is 
mandatory for blood donors who present with risk of ma-
laria to be deferred for 6 months up to 4 years, depending 
on the severity of their exposure risk to the Plasmodium 
parasite. Furthermore, during the last 2 decades many 
transfusion centres in western countries, including 
France, the UK, Australia, Denmark, Finland, New Zea-
land, and Switzerland, and partly volunteer-based centres 
in Germany, have implemented selective malaria anti-
body screening programmes to identify donors with pre-
vious malaria infection [5, 12–16].
Blood smear tests, RDTs, and PCRs are not suitable for 
screening of potentially infected blood donors and thus 
ELISA-based tests were developed to test for specific anti-
Plasmodium antibodies in blood donations [17, 18]. 
These serological tests often apply parasite antigens from 
non-sexual blood stages, which are the main target of the 
immune response. Therefore, Plasmodium-specific anti-
bodies are detected at the earliest 1 or 2 weeks after the 
initial infection [19]. Most of the commercially available 
ELISAs use antigens derived from P. falciparum and P. 
vivax. The detection of antibodies against other malaria 
species (e.g., P. ovale, P. malariae, and P. knowlesi) thus 
relies solely on cross-reactivity of antibodies to the P. fal-
ciparum and P. vivax antigens. Although in most cases 
there are indeed cross-reactive antigens to these antigens, 
there are reports showing reduced sensitivity for the de-
tection of antibodies generated against the other malaria 
species [14]. To combat this discrepancy, several recently 
developed ELISA tests have begun to include further an-
tigens from P. ovale and P. malariae [18]. So far, however, 
the detection of specific antibodies against P. knowlesi has 
not been included in any blood donor-screening ELISA.
Here, we report a prospective study evaluating the se-
rological screening of blood donors originating from ma-
laria-endemic regions and travellers returning from such 
regions for anti-Plasmodium spp. antibodies to assess the 
performance of the first commercial ELISA (EUROIM-
MUN EIA) using recombinant antigens for all 5 human 
pathogenic Plasmodium species. This ELISA was com-
pared to 2 established Plasmodium species ELISA tests 
used in routine blood donor screening at two different 
laboratory centres. Confirmatory testing of reactive sam-
ples was conducted at the Swiss National Reference Cen-
tre for Imported Parasitic Diseases at the Diagnostic Cen-
tre of the Swiss Tropical and Public Health Institute 
(Swiss TPH) in Basel, Switzerland.
Materials and Methods
Sample Origin and Collection Strategy
Plasma samples were collected prospectively from December 1, 
2015 until November 30, 2016. The samples were selected from 
adult blood donors (≥18 years) who had reported visiting a malar-
ia-endemic region since their previous donation or were born and/
or lived in a malaria-endemic region for more than 6 months. The 
study was conducted at two blood transfusion laboratories: the In-
stitute for Laboratory and Transfusion Medicine, Bad Oeynhausen 
(centre 1, Germany), where 612 plasma samples were collected 
(collective A), and the Interregional Blood Transfusion Centre 
SRC, Bern (centre 2, Switzerland), where 502 samples were col-
lected (collective B).
Testing Strategy
Study samples were analysed by the two respective centres us-
ing the screening Malaria ELISA routinely applied at that centre. 
Additionally, both centres analysed the samples with the novel An-
ti-Plasmodium ELISA IgG (EUROIMMUN, Germany). Those 
samples reactive for anti-Plasmodium IgG in the corresponding 
screening ELISA or the EUROIMMUN index ELISA were sent to 
the Swiss TPH for confirmation. Negative samples in the screening 
ELISA and the index test were not forwarded for confirmation. 
Samples above the cut-off with the CAPTIATM Malaria EIA, Trin-
ity Biotech (centre 1), and with the Malaria EIA, BioRad (centre 2) 
were considered reactive in concordance with the routine proce-
dures at the blood donation centres. For the purpose of this study, 
reactive samples and samples in the borderline range between the 
ratio of 0.8 and 1.1 using the index ELISA from EUROIMMUN 
were also considered reactive and thus sent for confirmation. All 
inconclusive and positive results determined at the Swiss TPH 
were considered confirmed reactive.
Index Test: Anti-Plasmodium ELISA IgG, EUROIMMUN
The index ELISA was developed to qualitatively and semi-
quantitatively detect antibodies in human serum or plasma to all 5 
pathogenic Plasmodium species (P. falciparum, P. vivax, P. ovale, 
P. malariae, and P. knowlesi). The test uses microtitre plates coat-
ed with a mixture of recombinant target antigens from all 5 species. 
Specific antibody binding is visualised by the addition of an anti-
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human IgG conjugated to peroxidase, which catalyses the colour 
change of the chromogenic substrate TMB/H2O2. The ELISA was 
conducted according to the manufacturer’s instructions and the 
results are reported as the extinction ratio of sample to calibrator. 
Samples are positive with a ratio ≥1.1. A borderline range is de-
fined for a ratio between 0.8 and 1.1. Within this study, samples 
with borderline or positive results were classified as reactive.
Screening Tests: CAPTIATM Malaria EIA, Trinity Biotech 
(Centre 1) and Malaria EIA, BioRad (Centre 2)
According to the test instructions, both kits are manufactured 
by Trinity Biotech and use exactly the same antigens for detection 
of total anti-malaria antibodies. Therefore, we consolidated both 
assays under the term “screening ELISA.” Both ELISAs detect 
qualitatively and semi-quantitatively antibodies against P. falci-
parum, P. vivax, P. ovale, and P. malariae in human serum or plas-
ma. The microtitre plates are coated with total protein extract from 
P. falciparum and a recombinant antigen from P. vivax. Due to 
antigenic similarity between the Plasmodium species P. ovale and 
P. malariae, the manufacturer reports that antibodies to these spe-
cies are detected as well with this assay. The total malaria antibody 
binding from donor samples is visualised by addition of the same 
antigens conjugated to horseradish peroxidase. Both ELISAs were 
conducted according to manufacturer’s instructions. The cut-off 
was set as the mean of the negative controls plus 0.100 optical den-
sity units; no borderline range was defined in routine use. In this 
study, all samples above the cut-off were considered reactive.
Reference Test: Malaria ELISA and IFAT
The reference strategy chosen for this study is that used rou-
tinely for malaria antibody testing in all Swiss blood donation cen-
tres and follows the algorithm described in the national guidelines 
of the Blood Transfusion Service of the Swiss Red Cross [20]. Brief-
ly, it states that all risk donations must be screened by an addi-
tional independent ELISA or IFAT (indirect immunofluorescence 
test). Those donations with a negative result for Plasmodium spp. 
antibodies are regarded as free from Plasmodium and all blood 
products from this donation can be released for transfusion. All 
samples reactive in the screening ELISAs at the test centre were 
sent for confirmation to the Swiss TPH with their in-house ELISA 
and IFAT that use antigens of cultured P. falciparum erythrocytic 
stages. The in-house ELISA in combination with the IFAT exhibits 
a sensitivity of >99% for P. falciparum, P. vivax, P. malariae, P. 
ovale, and P. knowlesi antibodies for blood samples taken >1 week 
after the first fever episode. Sensitivity is considerably reduced for 
blood samples taken <1 week after the onset of symptoms for in-
fections with all Plasmodium spp. due to lack of seroconversion 
(see online suppl. Table 1; for all online suppl. material, see www.
karger.com/doi/10.1159/000515842). The specificity of the com-
bined test is >99% for healthy donors. Cross-reactivity with infec-
tions of other blood protozoa species cannot completely be ex-
cluded.
P. falciparum spp. ELISA
Malaria serology was performed with an in-house screening 
ELISA for detection of specific Plasmodium spp. antibodies. P. fal-
ciparum antigen (strain NF54) from erythrocytic stages was coated 
in 0.05 M sodium carbonate buffer, pH 9.6, to Immulon 2HB plates 
(ThermoScientific, Wohlen, Switzerland). After washing, diluted 
plasma samples were added to the plates and incubated for 15 min 
at 37°C. After additional washing steps, horseradish peroxidase 
conjugated goat-anti-human IgG (KPL, 474-1006, BioConcept 
Ltd, Allschwil, Switzerland) was added. Plates were incubated for 
15 min at 37°C, subsequently washed, and o-Phenylendiamine Di-
hydrochloride (OPD, Sigma, Buchs, Switzerland) was added. The 
reaction was stopped with 8 M H2SO4, and absorption was read 
with a Multiscan FC reader (ThermoScientific) at 492 nm. The cut-
off OD for the ELISA was <0.15, inconclusive range OD was 0.15–
0.29, and positive OD was ≥0.30. All plasma samples giving posi-
tive or equivocal results were additionally tested with an in-house 
confirmatory malaria IFAT.
Malaria IFAT Test
Immunofluorescence staining was performed with cultured 
erythrocytic stages of P. falciparum (strain NF54) mounted on 
glass slides. Slides were stored at −80°C until the day of use. For 
Samples of blood donors approached for screening: n = 1,114  
 (centre 1: n = 612, centre 2: n = 502)  
Excluded: n = 18  
(centre 1: n = 17, centre 2: n = 1)  
n = 8: invalid test run  
n = 5: inappropriate storage  
n = 5: not enough volume  
Samples of blood donors included in study measurements: n = 1,096  
(centre 1: n = 595, centre 2: n = 501)  
Reactive in any tested ELISA: n = 83  
(centre 1: n = 34, centre 2: n = 49)  
Negative in any tested ELISA: n = 1,013  
(centre 1: n = 561, centre 2: n = 452)  
Positive in confirmation testing at Swiss TPH:   n = 4  
Inconclusive in confirmation testing at Swiss TPH:  n = 16 
Negative in confirmation testing at Swiss TPH:   n = 63 Fig. 1. Algorithm for the comparison of the 
two screening assays with the EUROIM-
MUN index assay.
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IFAT analysis, the slides were quickly air dried at room tempera-
ture and then fixed with acetone. Plasma samples were diluted in 
PBS pH 7.2 and applied to the slide slots. Three control samples 
were present on each slide: 1 positive, 1 equivocal, and 1 negative 
control. After 25 min of incubation at 37°C in a wet chamber, the 
slides were washed with PBS pH 7.2 and air dried. FITC conju-
gated F(ab)’2 anti-IgG/A/M (BioRad, No. 30244) diluted in 0.01% 
Evans blue in PBS was added and the slides were incubated for 25 
min at 37°C, washed, dried, and a cover glass was mounted with 
buffered glycerol. Slides were examined immediately with a fluo-
rescence microscope. The IFAT exhibits a sensitivity of >99% for 
Plasmodium spp. and a specificity of >99% for healthy blood donor 
samples (see the appendix of online suppl. Table 1)
The results of the combined ELISA and IFAT confirmation 
tests are reported as positive, inconclusive, or negative. If these 
confirmation tests are negative, then the blood donation is consid-
ered free of malaria and the corresponding blood products are re-
leased for transfusion. Those samples classified as positive or in-
conclusive are considered to pose a risk of transmitting Plasmo-
dium via blood transfusion, even if this represents an antibody titre 
from a previous infection, and the blood products are destroyed. 
These donors are deferred for at least 3 years due to safety reasons.
Results
Comparison of Performance of Screening and Index 
ELISAs
During the 1-year study period, 1,114 samples were 
screened in both test centres. After the exclusion of 18 
samples for various reasons (17 from centre 1 and 1 from 
centre 2), 1,096 samples were included in the study. Fig-
ure 1 shows the sample distribution by the two study sites 
and the flow of patient samples. In total, 83 of 1,096 reac-
tive samples (7.6%) were identified in the screening or 
index ELISAs. The number of reactive samples identified 
at the two centres was: 34 out of 595 (5.7%) at centre 1, 
and 49 out of 501 (9.8%) at centre 2.
At centre 1 (n = 595), 11 samples were reactive in the 
screening ELISA while 32 samples were reactive in the 
index test (Table 1). Discrepant results were obtained for 
25 samples, whereas only 9 samples were consistently re-
active and 561 samples were negative by both tests. At 
centre 2 (n = 501), 31 samples were reactive with the 
screening ELISA and 37 samples were reactive with the 
index ELISA. From these 49 reactive samples, 30 were re-
active with either the index or screening ELISA, whereas 
19 samples were reactive in both assays. The remaining 
452 samples were negative (Table 2). The overall concor-
dance of 95.8% was determined at centre 1, and 94.0% at 
centre 2.
Confirmation at the Reference Centre
All 83 samples reactive in the screening or index anti-
Plasmodium ELISAs were sent to the Swiss TPH for con-
firmation. From the 28 samples which were reactive in 
both the index and screening ELISAs, 4 were confirmed 
positive, 9 cases showed an inconclusive result, and a fur-
ther 15 samples were classified as negative (Fig. 2). None 
of the 14 samples reactive in the screening but negative in 
index ELISA were confirmed positive; however, 3 sam-
ples yielded an inconclusive result and 11 were negative. 
Likewise, none of the 41 samples initially negative in the 
screening ELISA but positive in the index test were con-
firmed positive at the reference centre; however, 4 sam-
ples showed an inconclusive result and a further 37 sam-
ples were negative. Thus, following the reference strategy, 
from the 42 samples which were reactive in the screening 
ELISAs, 16 samples were declared positive (4 positive and 
12 inconclusive samples) by the Swiss TPH.
Calculations of prevalence, sensitivity, and specificity 
of the index EUROIMMUN anti-Plasmodium ELISA 
(IgG) test were performed against the reference strategy. 
As 17 samples were finally confirmed positive or incon-
clusive after confirmation testing (i.e., 4 positive and 13 
inconclusive samples from 1,096), an anti-Plasmodium 
antibody prevalence in blood donations of 1.55% was cal-
culated. Of the 20 confirmed reactive samples, 17 samples 
were detected by the index test, resulting in an assay sen-
sitivity of 85.0%. The specificity of 95.2% was calculated 
(1,024 out of 1,076 confirmed negative samples).
Discussion
In non-endemic countries, the risk of TTM is often 
linked to asymptomatic infections acquired during previ-
ous residency or travel activities in endemic regions com-
bined with semi-immunity. Selective screening of blood 
donors with risk for infections with Plasmodium spp. us-
ing serological assays has demonstrated to be a feasible 
and cost-effective strategy to minimize the number of re-
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jected blood donations but keep a high blood safety [5, 7, 
13, 14, 17, 21, 22].
In this study, the novel EUROIMMUN anti-Plasmodi-
um ELISA (IgG) was compared to the current screening 
ELISAs routinely used at two independent blood transfu-
sion centres in order to test blood donors at risk for hav-
ing acquired malaria. The new anti-Plasmodium ELISA 
(IgG) exhibited a high concordance to the routine screen-
ing test at both centres (95.8%: centre 1, and 94.0%: centre 
2). The relative discrepancy of 5.0% between the screen-
ing and index results may be attributed to the different 
antigenic substrates used in the different ELISA tests. 
Furthermore, the screening ELISA produced by Trinity 
Biotech uses protein extract from P. falciparum and a re-
combinant antigen from P. vivax, whereas the anti-Plas-
modium ELISA (IgG) from EUROIMMUN applies re-
combinant antigens from all 5 human pathogenic Plas-
modium species. Moreover, a borderline range is defined 
for the results obtained with the anti-Plasmodium ELISA 
(IgG). In favour of a high blood safety level, all the bor-
derline results were considered reactive.
Being in line with the idea of a two-step reference strat-
egy, only a subset of reactive results obtained with the 
screening test were confirmed positive at the reference 
centre (4 of 42). All 4 samples were also found to be reac-
tive by both the EUROIMMUN Index and ELISA and 
Trinity Biotech screening ELISAs.
Sensitivity and specificity calculations for the index 
EUROIMMUN test were performed against the reference 
strategy yielding 85.0 and 95.2%, respectively. All 4 sam-
ples reactive with the EUROIMMUN ELISA were con-
firmed reactive at the Swiss TPH but were negative with 
the Trinity Biotech ELISA. Likewise, 3 samples reactive 
with the screening ELISA were confirmed at the Swiss 
TPH but were negative with the index ELISA. The Trin-
ity Biotech screening ELISA thus achieved a sensitivity of 
80.0% (16 out of 20 confirmed reactive samples) and a 
specificity of 97.6% (1,050 out of 1,076).
Although the sensitivity is not very high, the testing 
approach nevertheless reduces the operational impact of 
addressing a minimal risk from travellers and offers im-
provement over deferral by testing all former residents of 
endemic areas. Despite the current international regula-
tory requirements, the current national policies have 
“evolved” through a series of additions and revisions to 
the guidelines as concerns and issues arose in each coun-
try. This has led to relatively high variability in donor se-
lection criteria currently used internationally. In non-en-
demic countries, the prevention of imported malaria is 
addressed by two distinct strategies. The donors must be 
deferred for long enough after returning from an endem-
ic region, thus allowing the potentially infected donors to 
develop symptoms or resolve the infection. Alternatively, 
they are tested for signs of malaria disease after a shorter 
deferral period [17]. The following limitations of our 
study should be pointed out, however. Samples that were 
negative in the initial screening ELISA were only con-
firmed negative by the index ELISA, but not at the refer-
ence laboratory. The confirmation of negative test results 
is currently not required in current routine strategy used 
in the blood centres and was therefore not actively pur-
sued. Although considered rather unlikely, it cannot be 
excluded that the different initial ELISAs may miss sam-
ples that are reactive with the malaria ELISA and IFAT 
Fig. 2. Further analysis of reactive samples from the screening and the EUROIMMUN index assays at the Na-
tional Reference Centre for Imported Parasitic Diseases at the Swiss TPH.
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using total P. falciparum antigens as is used at the refer-
ence laboratory. In addition, since the EUROIMMUN 
ELISA also contains P. knowlesi protein antigens, it could 
be one possible explication that non-confirmed positive 
results from the EUROIMMUN ELISA may arise form 
from P. knowlesi-specific antibodies that do not cross-
react with the P. vivax and P. falciparum antigens. Infor-
mation on the direct clinical or the geographical history 
of the blood donors is mostly lacking. A direct detection 
of the pathogen by either molecular testing or microscopy 
is considered not feasible due to low-level parasitaemias 
in the blood donor samples. For these reasons, it is diffi-
cult to investigate possible reasons for the observed dis-
crepancies between the two test systems.
Conclusion
This study shows the necessity of selective screening of 
blood donations for anti-Plasmodium antibodies in blood 
transfusion centres in Germany and Switzerland, two 
non-endemic regions. Four Plasmodium IgG-positive 
blood donations were identified using both the screening 
and index tests and confirmed with the reference labora-
tory tests. It is possible these donations were from donors 
with an active malaria infection and thus posed a poten-
tial source of TTM. On the other hand, the reactive sam-
ples could also have originated from donors with a per-
sistent high antibody titre from a previously treated ma-
laria case. As the national guidelines request, these 
donations were rejected due to safety reasons.
Of course, with the used approach of a serological test 
based on the questionnaire there will never exist a 100% 
safety in terms of Plasmodium spp. An advantage of rou-
tine screening for anti-Plasmodium antibodies of blood 
donations with increased risk is that a negative screening 
result leads to a reduced deferral period of the corre-
sponding donor. In this way, the profitability of the blood 
banks is maximized without compromising blood safety. 
The comparison of the new EUROIMMUN ELISA and 
the established CAPTIATM Malaria EIA (Trinity Biotech) 
and Malaria EIA (BioRad) used for routine blood donor 
screening in two laboratory centres reveals that all three 
ELISAs are equally suitable for anti-Plasmodium anti-
body screening in blood banks.
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